Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441021 | 1.00 | HDAC1 (0.45) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6439435 | 0.94 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6439438 | 0.94 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6437657 | 0.90 | ESR1 (0.43) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6437655 | 0.90 | ESR1 (0.43) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6438035 | 0.87 | ESR1 (0.41) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6438036 | 0.87 | ESR1 (0.41) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6437026 | 0.86 | HDAC1 (0.45) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6437030 | 0.86 | HDAC1 (0.45) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL14289701 | 0.84 | ESR1 (0.39) | HDAC1HDAC2HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | claimed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | claimed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | claimed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | claimed |
| US-7323587-B2 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| US-7045540-B2 | Selective estrogen receptor modulators | BRISTOL MEYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050267183-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-12-01 | — | — | US | disclosed |
| US-20050245602-A1 | Selective estrogen receptor modulators | KALTENBACH ROBERT F | 2005-11-03 | — | — | US | disclosed |
| US-6927224-B2 | Selective estrogen receptor modulators | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1417169-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245602-A1 | Selective estrogen receptor modulators | ESR1, ESR2, GPER1 | HDAC1 2887/4885HDAC2 2417/4885HDAC3 1559/4885 |
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | HDAC1 1964/4885HDAC2 2368/4885HDAC3 1502/4885 |
| US-20050267183-A1 | Selective estrogen receptor modulators | ESR2, ESR1, GPER1 | HDAC1 2935/4885HDAC2 2520/4885HDAC3 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.